Ocugen

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152)

MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) this week announced positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening study of its COVID-19 vaccine candidate, COVAXINâ„¢ (BBV152; Clinicaltrials.gov, NCT05258669), …

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152) Read More

cancer

Study: Cancer Patients Treated with Immunotherapy Can Safely Receive mRNA COVID-19 Vaccines

PLYMOUTH MEETING, PA — New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment. The researchers …

Study: Cancer Patients Treated with Immunotherapy Can Safely Receive mRNA COVID-19 Vaccines Read More



NRx Pharmaceuticals

NRx Announces Publication of Initial Findings of BriLife Vaccine-produced Antibodies Against Omicron Variant

RADNOR, PA — NRx Pharmaceuticals (NASDAQ: NRXP) states it has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective levels of …

NRx Announces Publication of Initial Findings of BriLife Vaccine-produced Antibodies Against Omicron Variant Read More